NCT00389285 - Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions

Carcinoma, Renal Cell

Interventions

DRUG

rIL-21 only

Part 1: rIL-21, IV, Day 1-5 and 15-19 of each 6-week treatment course

DRUG

rIL-21 + sorafenib

Part 2: rIL-21 IV, Day 1-5 and 15-19 of each 6-week treatment course + sorafenib (up to 400 mg taken orally twice daily)

Trial Locations (3)

University of Alabama, Birmingham

Premiere Oncology of Arizona, Scottsdale

Dartmouth-Hitchcock Medical Center, Lebanon